Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association(ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.

The poster presentation is a post-hoc analysis of Type 2 diabetes patients from Amarin’s ANCHOR trial who, despite statin therapy, have persistent high triglyceride levels. The 12-week ANCHOR trial studied the effects of Vascepa in adult patients at high risk for cardiovascular disease with persistent high triglyceride levels (≥200 mg/dL and < 500 mg/dL) after stable statin therapy.

Presentation information is as follows:

  • Poster Presentation #173-P, Category 12-E Clinical Therapeutics/New Technology-Oral Agents: Effects ofIcosapent Ethyl on Lipoprotein Particle Concentration and Size in Statin-Treated Patients with Persistent High Triglycerides: ANCHOR Patients with Diabetes Mellitus — (Authors: Eliot A. Brinton, MD, FAHA, FNLA, Christie M. Ballantyne, MD, Harold E. Bays, MD, et al.)
    • The poster will be on display from Saturday, June 11 starting at 10 a.m. CDT to Monday, June 13 at 2 p.m. CDT, with the author presentation scheduled for Sunday, June 12, between 12:00 – 2:00 p.m. CDT.

Additional data that was accepted by the ADA Scientific Sessions Planning Committee and will be published in the Diabetes® Abstract Book is titled: “Eicosapentaenoic Acid, but not other TG-lowering Agents, Reversed Hyperglycemia-Induced Rat Endothelial Cell Dysfunction and Enhanced the Benefits of Atorvastatin Active Metabolite Ex Vivo” (Authors: R. Preston Mason, PhD, Robert F. Jacob, PhD, Hazem Dawoud, MS, Haidar Alhumaid, MS, et al.). This was an ex vivo experiment looking at the effects of eicosapentaenoic acid ± atorvastatin active metabolite (ATM) relative to niacin or fenofibrate in glomerular endothelial cells from rats exposed to high glucose. (Original Source)

Shares of Amarin closed last Friday at $2.23, up $0.01 or 0.45%. AMRN has a 1-year high of $2.65 and a 1-year low of $1.24. The stock’s 50-day moving average is $1.80 and its 200-day moving average is $1.68.

On the ratings front, Amarin has been the subject of a number of recent research reports. In a report issued on May 31, Jefferies Co. analyst Hugo Ong reiterated a Buy rating on AMRN, with a price target of $3.50, which represents a potential upside of 57.0% from where the stock is currently trading. Separately, on May 27, Oppenheimer’s Carlos Solorzano assigned a Hold rating to the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Hugo Ong and Carlos Solorzano have a total average return of 3.5% and 13.7% respectively. Ong has a success rate of 63.6% and is ranked #1755 out of 3894 analysts, while Solorzano has a success rate of 90.0% and is ranked #903.

Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics to improve cardiovascular health. Its product, Vascepa capsules, is use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.